REVIEW

Recent advances in pathophysiology of disseminated intravascular coagulation: the role of circulating histones and neutrophil extracellular traps [version 1; peer review: 2 approved]

Yasir Alhamdi ¹, Cheng-Hock Toh^{1,2}

¹Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

²Roald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool University Hospital, Liverpool, UK

V1 First published: 18 Dec 2017, 6(F1000 Faculty Rev):2143
<https://doi.org/10.12688/f1000research.12498.1>

Latest published: 18 Dec 2017, 6(F1000 Faculty Rev):2143
<https://doi.org/10.12688/f1000research.12498.1>

Abstract

Disseminated intravascular coagulation (DIC) is an acquired condition that develops as a complication of systemic and sustained cell injury in conditions such as sepsis and trauma. It represents major dysregulation and increased thrombin generation *in vivo*. A poor understanding and recognition of the complex interactions in the coagulation, fibrinolytic, inflammatory, and innate immune pathways have resulted in continued poor management and high mortality rates in DIC. This review focuses attention on significant recent advances in our understanding of DIC pathophysiology. In particular, circulating histones and neutrophil extracellular traps fulfil established criteria in DIC pathogenesis. Both are damaging to the vasculature and highly relevant to the cross talk between coagulation and inflammation processes, which can culminate in adverse clinical outcomes. These molecules have a strong potential to be novel biomarkers and therapeutic targets in DIC, which is still considered synonymous with 'death is coming'.

Keywords

DIC, neutrophil extracellular, Thrombin

Open Peer Review

Approval Status

	1	2
version 1		
18 Dec 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Craig N Jenne**, University of Calgary ,
Calgary, Canada
2. **Julie Helms**, Strasbourg University Hospital,
Strasbourg, France

Any comments on the article can be found at the end of the article.

Corresponding author: Cheng-Hock Toh (Toh@liverpool.ac.uk)

Author roles: Alhamdi Y: Writing – Original Draft Preparation, Writing – Review & Editing; Toh CH: Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Alhamdi Y and Toh CH. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Alhamdi Y and Toh CH. **Recent advances in pathophysiology of disseminated intravascular coagulation: the role of circulating histones and neutrophil extracellular traps [version 1; peer review: 2 approved]** F1000Research 2017, **6** (F1000 Faculty Rev):2143 <https://doi.org/10.12688/f1000research.12498.1>

First published: 18 Dec 2017, **6**(F1000 Faculty Rev):2143 <https://doi.org/10.12688/f1000research.12498.1>

Introduction

Disseminated intravascular coagulation (DIC) represents a major dysfunction in the hemostatic system, which is a physiological response to vascular injury. Upon injury, immediate interactions between components of the vessel wall and circulating blood lead to activation of the extrinsic and intrinsic pathways of coagulation to generate a burst of thrombin. Thrombin is immediately pro-coagulant in converting fibrinogen to fibrin but also mediates the anti-coagulant pathway by interacting with thrombomodulin (TM) to activate the protein C (PC) pathway. This controls the extent of localized clot formation, but when injury is of a systemic or sustained nature, regulation of thrombin generation is lost with adverse functional consequences. Owing to the ubiquitous nature of thrombin in affecting coagulation, fibrinolysis, and inflammation¹⁻³, this can result in DIC and cause organ failure from microvascular thrombosis and endothelial barrier disruption.

This dynamic complexity in DIC pathogenesis is clinically important because its presence is well validated as an independent predictor of mortality⁴. Development of DIC significantly increases risk of death beyond that of the underlying pathology. For example, DIC development in patients with sepsis and trauma doubles the risk of mortality⁵. Despite this awareness, and the fact that its acronym could stand for 'death is coming', it remains poorly recognized by critical care clinicians and poorly managed because of the lack of high-quality evidence. DIC diagnosis is based on scoring a number of hemostatic parameters⁶. Although measurements of the prothrombin time, fibrinogen, platelets, and fibrin-related products are generally available, changes in all of these parameters may not occur at the same time and can delay recognition and diagnosis. In some critical care settings, not all of these tests might be requested. Together with the lack of understanding that the manifestation of DIC can vary depending on primary disease-specific drivers of thrombin generation in causing multi-organ failure, this has resulted in poor management and mortality rates of 50%⁷.

With the overall aim of improving our understanding of how DIC contributes to adverse clinical outcomes, this review will build upon key criteria in DIC. These were set out by the International Society on Thrombosis and Hemostasis (ISTH) Scientific and Standardization Sub-Committee (SSC) in describing how DIC can arise from the vasculature but also cause damage to the vasculature⁴. Furthermore, the direct coupling of inflammation to coagulation processes facilitates the development of organ dysfunction. Specifically in this review, we will examine how extracellular histones and neutrophil extracellular traps (NETs) fit the DIC criteria and key principles in our understanding of DIC pathogenesis. Insight into this rapidly growing area of research could pave the way for improved clinician understanding and better approaches to manage the patient with DIC.

Extracellular histones and neutrophil extracellular traps

While the intra-nuclear function of histones as proteins that package DNA into nucleosomes has been well understood^{7,8}, it is

their role when released extracellularly upon cellular damage or death that is of interest and relevance to DIC. The cytotoxicity of extracellular histones, whereby their neutralization in sepsis models with anti-histone antibodies or activated PC (APC) conveyed survival benefit were first described in 2009⁹. This discovery, followed by further *in vitro* and *in vivo* work, has translated into studies in patients with sepsis, trauma, and pancreatitis to illustrate the clinical relevance of extracellular histones and histone-DNA complexes (nucleosomes) to systemic inflammation, microvascular thrombosis¹⁰⁻¹⁴, organ injury^{10,11,15-18}, and death. Extracellular histones may be found in the circulation (either free or complexed with DNA 'nucleosomes') or localized (and modified) as part of the extracellular traps released upon damage or activation of nucleated cells, primarily neutrophils. The various roles of neutrophils as key modulators of the complex interaction between innate immunity, inflammation, and coagulation (also known as 'immunothrombosis') are increasingly recognized and were recently well reviewed by Stiel *et al.*¹⁹. The focus of this review is on one aspect of neutrophil contribution; which is mediation by NETs.

NETs were first described in 2004 as a neutrophil-derived amalgam of elastases, histones, and DNA that collectively trap and kill bacteria²⁰. Like histones, NETs have important physiological but potential pathological manifestations. Their uncontrolled or inappropriate release by neutrophils can contribute to the pathogenesis of sepsis, micro- and macro-vascular thrombosis, and multiple organ injury²¹⁻²⁶. Consequences of NETs are typically site-specific, but breakdown products, such as cell-free DNA (cfDNA) or DNA-myeloperoxidase (DNA-MPO) complexes, can be found in the circulation²⁷⁻³¹. However, cfDNA can arise from damaged cells and not only from NETs³². As such, high circulating cfDNA levels should not be assumed to correlate directly with *in vivo* NET formation. Furthermore, intact NETs are structurally different and functionally dependent on its associated contents both locally and when cleaved and present in the circulation^{33,34}.

Importantly, there is a bi-directional relationship between NETs and histones (Figure 1). First, NETs bear exposed histones (and numerous potent enzymes such as elastase) on their meshwork and therefore facilitate local histone-mediated cytotoxicity, pro-coagulant and pro-inflammatory effects. Histones can also be released from NETs into the circulation to disseminate its adverse effects^{35,36}. Second, histones can directly stimulate neutrophils to form NETs^{10,37,38} and therefore there is a vicious circle triggered by cellular injury that is then propagated by this bi-directional relationship between histones and NETs to promote further thrombin generation and contribute to DIC pathogenesis. These will be specifically detailed below in addressing how the various pathophysiological aspects of DIC can be contributed to by circulating histones and NETs.

Relevance of histones and neutrophil extracellular traps to disseminated intravascular coagulation

The discussion will be divided into how histones and NETs contribute to the initiation, amplification, and propagation of coagulation activation (Table 1).

Figure 1. Bi-directional relationship between histones and neutrophil extracellular traps (NETs). Cell damage releases histones which trigger NET formation and the formed NETs are a source for both localized and systemic histone release. The increased thrombin generation, which is the hallmark of disseminated intravascular coagulation, simultaneously affects coagulation, fibrinolysis, and inflammation processes to amplify the reciprocal relationship between histones and NETs.

Table 1. Mechanisms by which histones and neutrophil extracellular traps cause disseminated intravascular coagulation.

Triggering coagulation

- Tissue factor expression on endothelial cells and macrophages (mediated by Toll-like receptors and pro-inflammatory pathways: nuclear factor-kappa B and activator protein 1)^{12,39}
- Neutrophil extracellular traps bearing tissue factor⁴⁰⁻⁴²
- Pro-inflammatory cytokine release, production, and activation^{10,43-48}
- Cellular activation and injury, including platelets^{9,10,13,26,49-54}

Amplifying coagulation

- Reduced endogenous anti-coagulant activity by consumption, liver damage, and extravascular extravasation^{12,16,55-59}
- Intrinsic pathway activation⁶⁰⁻⁶³
- Impaired fibrinolysis⁶⁴⁻⁶⁶

Propagating coagulation

- Cytotoxic effects in circulation^{9,10,15,49,59,67-69}
- Circulating microparticle effects⁷⁰⁻⁷³
- Distant organ injury^{9,10,15,74}

Factors that trigger coagulation in disseminated intravascular coagulation

Tissue factor expression. It is widely acceptable that the most important trigger of coagulation in sepsis and trauma-associated DIC is excessive tissue factor (TF) expression by circulating monocytes and its exposure from the vascular sub-endothelium following injury⁷⁵. This is supported by the observation that patients with DIC have significantly higher levels of circulating TF compared with controls⁷⁶. Exaggerated TF expression in septic and trauma DIC was historically attributed to systemic inflammation triggered by the invading microorganisms or their toxins (such as lipopolysaccharides)³⁹⁻⁴¹. However, two recent studies have shown that extracellular histones can directly induce TF expression in a dose- and time-dependent manner on the surface of

endothelial cells and macrophages via Toll-like receptor-4 (TLR-4) and TLR-2 and activation of the nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1) pathways^{12,42}. With regard to NETs, recent studies have reported that NETs bear TF and contribute to thrombosis in myocardial infarction⁷⁷ and anti-neutrophil cytoplasmic antibody-associated vasculitis^{78,79}. One study in the cancer setting reported significant interactions and correlations between NET components (primarily circulating DNA and nucleosomes) and TF-bearing microparticles culminating in overt DIC⁴³. Interestingly, both TF-bearing NETs and TF-bearing microparticles were found to be triggered by complement C5a⁷⁹, highlighting a significant interaction between the coagulant and innate immune systems that include complement in contributing to pathology.

Pro-inflammatory cytokine involvement. In sepsis and trauma, the DIC process is directly linked into, and triggered by, the systemic inflammatory host response, of which pro-inflammatory cytokines play critical roles beyond induction of TF expression⁴⁴. Excessive cytokine activities disrupt the fine balance and cross talk between coagulant, anti-coagulant, and inflammatory pathways to augment the pro-coagulant phenotype^{44,45}. Histones can directly induce the release of several pro-inflammatory cytokines, including interleukin-6 (IL-6), IL-1 β , and tumor necrosis factor-alpha (TNF- α)^{10,46–48}. NETs act as scaffolds to potentiate IL production and activation^{80–82}. Conversely, cytokines can induce NETosis⁸³ in a bi-directional relationship akin to that between histones and NETs (Figure 1).

Platelet activation. Platelets are important for both the initial burst and further sustenance of thrombin generation by acting as scaffolds on which further coagulation activation takes place⁸⁴ and through platelet-derived polyphosphate activation of factor XI⁸⁵. Platelets also promote a pro-coagulant phenotype via P-selectin expression which enables adherence to the vascular endothelium and leukocytes while also augmenting TF expression⁴⁹ and phosphatidylserine exposure on monocytes^{50,51} which collectively enhances thrombin generation⁵¹. Histones can directly induce platelet activation via calcium influx with subsequent platelet aggregation and consumption *in vitro* and *in vivo*^{13,52,86}. Histones can also promote thrombin generation in a platelet-dependent manner via P-selectin expression, phosphatidylserine exposure, and FV/Va availability on platelet surfaces⁸⁷. Histone-induced TF expression and subsequent thrombin generation can further activate platelets. In terms of clinical relevance, a case control study in intensive care patients recently illustrated a strong association between high histone levels and subsequent platelet consumption and thrombocytopenia to translate the findings of histone-induced thrombocytopenia in animal models⁸⁸. In parallel, NETs can interact with platelets to induce platelet aggregation, polyphosphate release, and subsequent thrombin generation to cause intravascular coagulation in septic mice²⁶. Conversely, platelets can directly induce NETosis^{33,89,90} (Figure 1) and contribute to pathology, including that of transfusion-associated acute lung injury^{33,90}.

Vascular endothelial injury. The vascular endothelium, one of the biggest organs in the body, has a natural anti-coagulant surface mediated by the generation of APC⁹¹, tissue factor pathway inhibitor (TFPI)⁹², and expression of heparan sulfate and glycosaminoglycans that convey anti-thrombin (AT) activity⁹³. Endothelial cells also participate in fibrinolysis through release of tissue plasminogen activator (tPA) upon activation^{94,95}. Therefore, damage or dysfunction of the vascular endothelium is another vital aspect of DIC pathogenesis. To this end, histone-induced toxicity on the vascular endothelium is well documented⁹ and further extended in clinical studies with strong correlations observed between levels of circulating histones and soluble TM, a marker of endothelial cell injury, in critically ill patients¹⁰. In addition, histones have been reported to induce the release of ultra-large von Willebrand factor (vWF) multimers⁹⁶, which are involved in platelet adhesion, platelet consumption, and microvascular thrombosis. Reports in patients

with sepsis have indeed documented elevated levels of ultra-large multimers of vWF together with deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13), which is responsible for degradation of these multimers^{53,54}, but the direct effect of histones on ADAMTS-13 is not currently known. As to NETs, a recent study showed that vascular endothelial cells have limited phagocytic capacity for NETs, which could result in poor NET clearance and subsequent damage to endothelial tight junctions to increase vascular permeability⁷⁷. Another study illustrated that matrix metalloproteinases within NETs contribute to endothelial dysfunction⁶⁷. Indeed, activated endothelial cells can also induce NETosis⁹⁸. As such, these histone- and NET-induced changes are also likely to play relevant roles in DIC pathogenesis.

A physical consequence of cellular injury induced by histones and NETs is the exposure of negatively charged phospholipid surfaces from membrane disruption⁹⁹. Availability of such phospholipid surfaces is highly pro-coagulant and can accelerate the prothrombinase reaction by 250,000-fold¹⁰⁰. In addition, histones can directly bind prothrombin and cause its auto-activation into thrombin. The implications would be that histones can directly generate thrombin without requiring coagulation activation¹⁰¹. Although this reaction takes about eight hours and therefore may not be physiologically relevant, the available evidence points to the diversity in how histones directly contribute to thrombin generation and disseminate coagulation activation.

Factors that amplify coagulation in disseminated intravascular coagulation

Reduced endogenous anti-coagulant activity. The three endogenous anti-coagulant pathways—AT, PC, and TFPI—play a critical role in regulating the extent of clot generation. All of these pathways are significantly compromised in DIC. Declining trends in AT and PC levels can be used to identify patients in a non-overt stage of DIC before full decompensation⁶. Low AT and PC levels have been validated as strong predictors of mortality in patients with sepsis and DIC^{55,102}.

Although low levels of endogenous anti-coagulants can be due to pathological consumption by the excessive coagulopathy in DIC, other mechanisms also contribute to reduced activity and levels¹⁰³. Related to histones and NETs are two studies showing that histones can disrupt the PC pathway by downregulating TM¹² or dampening TM-dependent PC activation⁵⁶. This would impair APC anti-coagulant, anti-inflammatory, and cyto-protective functions⁵⁷, including its ability to proteolytically cleave histones⁹. NET-associated elastases can potentially degrade AT and TFPI^{58–60}. In addition, two other potential mechanisms for endogenous anti-coagulant loss are reduced synthesis by the liver and loss to the extravascular space from enhanced vascular permeability⁶⁰. Histones can potentially contribute to both of these mechanisms by inducing liver injury and inflammation^{16,61} and significantly increasing vascular permeability through endothelial damage^{9,10}.

Intrinsic pathway activation. In physiological terms, the intrinsic pathway of coagulation plays an important role in increasing

thrombin generation and accelerating hemostatic clot formation. This is well exemplified by the significant bleeding issues in patients without factor VIII or IX. cfDNA- and NET-bound DNA can exert pro-coagulant effects through activating the intrinsic pathway of coagulation via FXI and FXII^{62,63}. Likewise, histones can activate the intrinsic pathway through an FXII-dependent mechanism, and histone-DNA complexes significantly contribute to elevated FXII in patients with overt DIC¹⁰⁴. Indirectly, histone-induced release of platelet polyphosphate can stimulate factor XI auto-activation as well as accelerate its thrombin-mediated activation¹⁰⁵.

Impaired fibrinolysis. Impaired or excessive fibrinolysis is an important aspect of sepsis- and trauma-induced DIC, respectively^{64,65,106}. All studies investigating the effects of histones, cfDNA, and NETs on the fibrinolytic system have consistently shown an overwhelmingly anti-fibrinolytic effect^{66,68,107}. This effect is mediated by enhanced clot resistance to fibrinolysis by plasmin and downregulation of plasminogen activation by tPA^{66,68,107}. As such, it appears that the effects of histones and NETs on the fibrinolytic system are relevant for sepsis-induced DIC but may not directly account for the hyper-fibrinolytic phenotype in trauma-associated DIC, although high histone levels in such patients may increase tPA release through significant endothelial stimulation and damage⁶⁹.

Factors that propagate coagulation in disseminated intravascular coagulation

The development of multiple organ injury further augments thrombin generation and dysfunction in DIC. Microvascular thrombosis can be triggered by the factors discussed above in leading to organ ischemia and failure. There is increasing understanding of the role mediated by circulating histones in particular. In addition to causing direct injury to endothelial and other hematopoietic cells^{9,10,52,99}, histones have been shown to mediate distant organ injury and dysfunction. In mice models of trauma¹⁰ and sepsis¹⁵, histones are major mediators of lung and cardiac injury and dysfunction, respectively. The clinical relevance of these findings has also been demonstrated in cohorts of critically ill patients with trauma¹⁰ and sepsis¹⁵. The evidence for the distant organ-damaging properties of histones in trauma comes from the consequent development of acute lung injury after significant non-thoracic trauma. Translational relevance is supported by the increased development of acute lung injury in patients with severe non-thoracic trauma with high histone levels. Similarly, sepsis patients without pre-existing cardiac disease were significantly more likely to develop new-onset cardiac arrhythmia (nine-fold increase) and left ventricular dysfunction (two-fold increase) if they had high histone levels¹⁵. Equally, circulating histones can mediate renal¹⁰⁸, liver^{91,109}, and brain¹⁰⁹ injury. Notably, the incubation of plasma or serum from critically ill patients (with sepsis, trauma, or pancreatitis) with cultured endothelial cells or cardiomyocytes induces cell death, which can be prevented in the presence of an antibody to histones^{10,15}.

Cellular damage is associated with microparticle formation and release^{70,71}. Their pro-coagulant properties include TF expression^{43,78,79}, as discussed above. Circulating microparticles from damaged or activated hematopoietic cells also have exposed

phosphatidylserine and these surfaces provide attachment sites for coagulation factors, which contribute to thrombotic complications in inflammatory disorders⁷². Significantly high levels of microparticles from activated endothelial cells and neutrophils were recently demonstrated in septic shock-induced DIC patients in whom elevated levels of NET surrogate markers (for example, nucleosomes and circulating DNA-MPO complexes) were evident⁷³. These microparticles may have synergistic pro-coagulant effects with NETs⁷² and prime neutrophils to undergo NETosis by facilitating a pro-inflammatory environment, including the release of pro-inflammatory cytokines^{74,110}.

These histone-induced cytotoxic effects not only are a manifestation of micro- and macro-vascular thrombosis due to the pro-coagulant effects described above but also are from direct cytotoxicity mediated by histone binding to cellular membranes with consequent pore formation, calcium influx, and overload^{10,11,52,99,111}. Fattahi *et al.* have demonstrated that after histone infusion into mice, histones localize (in order of concentration) in the lungs, spleen, kidneys, plasma, liver, heart, and brain¹¹². As histones unravel from DNA binding as part of nucleosomes, their cytotoxicity becomes apparent because of their ability to bind cell membrane phospholipids. However, in intact nucleosomes, where histone binding sites are covered by DNA, no cytotoxicity could be elicited⁸⁶. Collectively, these data suggest that circulating histones in patients with sepsis- or trauma-associated DIC are major mediators of distant organ injury and adverse clinical outcome.

Summary and insights for the future

In this review, we have highlighted how extracellular histones and NETs fulfil the most important principles of DIC pathophysiology, as established by the ISTH SSC⁴. First, histones can arise from endothelial cells following damage or from an exaggerated inflammatory response and in turn can mediate further significant damage to vascular endothelial cells. Directly and indirectly, histones can cause pro-inflammatory cytokine release and contribute to 'inflammation gone amok', as described in the ISTH communication⁴. With the bi-directional relationship between histones and NETs, along with their functional consequences (Figure 2), histones can be considered mediators of distant organ injury with NETs being the effectors of multi-organ failure.

As to how these findings can translate into better recognition of DIC, there are a number of studies showing histone-DNA complexes as important prognosticators in patients with DIC¹¹³, and their levels correlate with increasing DIC scores¹¹⁴. As such, there appears to be potential in using these molecules as biomarkers in early DIC before full decompensation occurs. This could be a major advancement in the diagnosis and management of critically ill patients at risk of DIC. One reason for this is that the current recommendations rely on a panel of coagulation tests collectively forming the 'DIC score', which signifies that the phenomenon is already under way or indeed advanced (overt DIC) rather than presents a target for early therapeutic intervention. Furthermore, the scoring system can vary between different societies and countries (for example, ISTH score, the Japanese Association for Acute Medicine Criteria, and the Japanese Ministry of Health and

Figure 2. Functional consequences of circulating histones and neutrophil extracellular traps (NETs). Summary of pro-coagulant, anti-fibrinolytic, pro-inflammatory, and cytotoxic effects of histones and NETs. IL, interleukin; NF-κB, nuclear factor-kappa B; TF, tissue factor; TNF-α, tumor necrosis factor-alpha.

Welfare score), and this impacts considerably on specificities/sensitivities of detection, stage of DIC (for example, overt or non-overt) identification, and prognostic values⁶⁰. Therefore, there is an area of unmet need for biomarkers that can better improve standardization in diagnosing DIC.

One difficulty facing the implementation of such biomarkers is that there is no simple, rapid test for quantifying histones that could be suitable for the acute hospital setting. Furthermore, there is controversy regarding the level of circulating histones; some papers quote levels in the microgram-per-milliliter range using Western blotting quantification^{10,15,88}, whereas others suggest that levels are in the nanogram-per-milliliter or picogram-per-milliliter range using enzyme-linked immunosorbent assay (ELISA)^{13,115,116}. From our experience, current ELISAs are not sufficiently specific for histone measurement in clinical samples and this is due to interference from other plasma proteins. The same issue applies to NET measurement in patient samples. Currently, most studies rely on measuring cfDNA, histone-DNA, and DNA-MPO complexes as surrogate markers of NET formation²⁷⁻³¹. Although these assays are a good development, they are also associated with problems relating to specificity, especially when the cfDNA may be released from other dying cells and not necessarily from NETs. Recent studies have illustrated promising potential for the use of neutrophil side fluorescence as a marker of neutrophil chromatin decondensation (hence NETosis) in predicting DIC development in patients with septic shock¹¹⁷. This new marker correlated significantly (yet with a weak correlation coefficient) with circulating nucleosomes and DNA-MPO complexes in patients with DIC⁷³. Standardization for histone and NET measurements using accurate high output techniques is therefore a pressing need.

Nonetheless, these are exciting challenges to overcome. There is the potential for novel therapeutic approaches using modalities that neutralize histones (APC⁹, anti-histone antibodies^{10,11,15}, recombinant TM¹³, and heparin¹¹⁸) or NETs (DNase²⁰, ADAMTS-13¹¹⁹, and PAD4-targeted therapy³⁴) or both. Many of these interventions are clearly anti-coagulant and could convey bleeding risk in patients with DIC if not used with caution. These would require well-designed randomized control trials using appropriate DIC patient populations (for example, with high circulating histones or NETs or both) as well as the potential for modified non-anti-coagulant versions as is the case with non-anti-coagulant heparins, which can neutralize circulating histones¹¹⁸.

Abbreviations

ADAMTS-13, disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; APC, activated protein C; AT, anti-thrombin; cfDNA, cell-free DNA; DIC, disseminated intravascular coagulation; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; ISTH, International Society on Thrombosis and Hemostasis; MPO, myeloperoxidase; NET, neutrophil extracellular trap; PC, protein C; SSC, Scientific and Standardization Sub-Committee; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TLR, Toll-like receptor; TM, thrombomodulin; tPA, tissue plasminogen activator; vWF, von Willebrand factor.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Wang W, Boffa MB, Bajzar L, *et al.*: **A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.** *J Biol Chem.* 1998; **273**(42): 27176–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Chen D, Dorling A: **Critical roles for thrombin in acute and chronic inflammation.** *J Thromb Haemost.* 2009; **7** Suppl 1: 122–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Narayanan S: **Multifunctional roles of thrombin.** *Ann Clin Lab Sci.* 1999; **29**(4): 275–80.
[PubMed Abstract](#)
4. Taylor FB Jr, Toh CH, Hoots WK, *et al.*: **Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.** *Thromb Haemost.* 2001; **86**(5): 1327–30.
[PubMed Abstract](#)
5. Fourrier F, Chopin C, Goudemand J, *et al.*: **Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.** *Chest.* 1992; **101**(3): 816–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Toh CH, Hoots WK, SSC on Disseminated Intravascular Coagulation of the ISTH: **The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.** *J Thromb Haemost.* 2007; **5**(3): 604–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Smith MM: **Histone structure and function.** *Curr Opin Cell Biol.* 1991; **3**(3): 429–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Kornberg RD, Lorch Y: **Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome.** *Cell.* 1999; **98**(3): 285–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Xu J, Zhang X, Pelayo R, *et al.*: **Extracellular histones are major mediators of death in sepsis.** *Nat Med.* 2009; **15**(11): 1318–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Abrams ST, Zhang N, Manson J, *et al.*: **Circulating histones are mediators of trauma-associated lung injury.** *Am J Respir Crit Care Med.* 2013; **187**(2): 160–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Alhamdi Y, Zi M, Abrams ST, *et al.*: **Circulating Histone Concentrations Differentially Affect the Predominance of Left or Right Ventricular Dysfunction in Critical Illness.** *Crit Care Med.* 2016; **44**(5): e278–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
12. Kim JE, Yoo HJ, Gu JY, *et al.*: **Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation.** *PLoS One.* 2016; **11**(6): e0156763.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Nakahara M, Ito T, Kawahara K, *et al.*: **Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism.** *PLoS One.* 2013; **8**(9): e75961.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Alhamdi Y, Toh CH: **The role of extracellular histones in haematological disorders.** *Br J Haematol.* 2016; **173**(5): 805–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Alhamdi Y, Abrams ST, Cheng Z, *et al.*: **Circulating Histones Are Major Mediators of Cardiac Injury in Patients With Sepsis.** *Crit Care Med.* 2015; **43**(10): 2094–103.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Wen Z, Lei Z, Yao L, *et al.*: **Circulating histones are major mediators of systemic inflammation and cellular injury in patients with acute liver failure.** *Cell Death Dis.* 2016; **7**(9): e2391.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
17. Liu T, Huang W, Szatmary P, *et al.*: **Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis.** *Br J Surg.* 2017; **104**(9): 1215–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Allam R, Kumar SV, Darisipudi MN, *et al.*: **Extracellular histones in tissue injury and inflammation.** *J Mol Med.* 2014; **92**(5): 465–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Stiel L, Meziani F, Helms J: **Neutrophil activation during septic shock.** *Shock.* 2017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
20. Brinkmann V, Reichard U, Goosmann C, *et al.*: **Neutrophil extracellular traps kill bacteria.** *Science.* 2004; **303**(5663): 1532–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
21. Kaplan MJ, Radic M: **Neutrophil extracellular traps: double-edged swords of innate immunity.** *J Immunol.* 2012; **189**(6): 2689–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Korkmaz HI, Ulrich MMW, Vogels S, *et al.*: **Neutrophil extracellular traps coincide with a pro-coagulant status of microcirculatory endothelium in burn wounds.** *Wound Repair Regen.* 2017; **25**(4): 609–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. Gloude NJ, Khandelwal P, Luebbeling N, *et al.*: **Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD.** *Blood.* 2017; **130**(10): 1259–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. Laridan E, Denorme F, Desender L, *et al.*: **Neutrophil extracellular traps in ischemic stroke thrombi.** *Ann Neurol.* 2017; **82**(2): 223–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. Dicker AJ, Crichton ML, Pumphrey EG, *et al.*: **Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease.** *J Allergy Clin Immunol.* 2017; pii: S0091-6749(17)30746-7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
26. McDonald B, Davis RP, Kim SJ, *et al.*: **Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice.** *Blood.* 2017; **129**(10): 1357–67.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. Sil P, Yoo D, Floyd M, *et al.*: **High Throughput Measurement of Extracellular DNA Release and Quantitative NET Formation in Human Neutrophils In Vitro.** *J Vis Exp.* 2016; (112): e52779.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
28. Hashiba M, Huq A, Tomino A, *et al.*: **Neutrophil extracellular traps in patients with sepsis.** *J Surg Res.* 2015; **194**(1): 248–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
29. Kraaij T, Tengström FC, Kamerling SW, *et al.*: **A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes.** *Autoimmun Rev.* 2016; **15**(6): 577–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Marin Oyarzún CP, Carestia A, Lev PR, *et al.*: **Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.** *Sci Rep.* 2016; **6**: 38738.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
31. Arai Y, Yamashita K, Mizugishi K, *et al.*: **Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation.** *Biol Blood Marrow Transplant.* 2013; **19**(12): 1683–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Choi JJ, Reich CF 3rd, Pisetsky DS: **Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro.** *Scand J Immunol.* 2004; **60**(1–2): 159–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Caudrillier A, Kessenbrock K, Gilliss BM, *et al.*: **Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury.** *J Clin Invest.* 2012; **122**(7): 2661–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Kolaczowska E, Jenne CN, Surewaard BG, *et al.*: **Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature.** *Nat Commun.* 2015; **6**: 6673.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. Kumar SV, Kulkarni OP, Mulay SR, *et al.*: **Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN.** *J Am Soc Nephrol.* 2015; **26**(10): 2399–413.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Saffarzadeh M, Juenemann C, Queisser MA, *et al.*: **Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones.** *PLoS One.* 2012; **7**(2): e32366.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Nakazawa D, Kumar SV, Marschner J, *et al.*: **Histones and Neutrophil Extracellular Traps Enhance Tubular Necrosis and Remote Organ Injury in Ischemic AKI.** *J Am Soc Nephrol.* 2017; **28**(6): 1753–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
38. Huang H, Tohme S, Al-Khafaji AB, *et al.*: **Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury.** *Hepatology.* 2015; **62**(2): 600–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
39. Aras O, Shet A, Bach RR, *et al.*: **Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia.** *Blood.* 2004; **103**(12): 4545–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Franco RF, de Jonge E, Dekkers PE, *et al.*: **The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation.** *Blood.* 2000; **96**(2): 554–9.
[PubMed Abstract](#)
41. Osterud B, Flaegstad T: **Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable**

- prognosis. *Thromb Haemost*. 1983; 49(1): 5–7.
[PubMed Abstract](#)
42. **F** Yang X, Li L, Liu J, *et al.*: Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF- κ B and AP-1. *Thromb Res*. 2016; 137: 211–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  43. **F** Hell L, Thaler J, Martinod K, *et al.*: OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients? *Thromb Res*. 2016; 140 Suppl 1: S174–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  44. Levi M, van der Poll T, ten Cate H, *et al.*: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. *Eur J Clin Invest*. 1997; 27(1): 3–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
  45. van der Poll T, de Jonge E, Levi M: Regulatory role of cytokines in disseminated intravascular coagulation. *Semin Thromb Hemost*. 2001; 27(6): 639–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
  46. Xu J, Zhang X, Monestier M, *et al.*: Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. *J Immunol*. 2011; 187(5): 2626–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  47. Allam R, Darisipudi MN, Tschopp J, *et al.*: Histones trigger sterile inflammation by activating the NLRP3 inflammasome. *Eur J Immunol*. 2013; 43(12): 3336–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
  48. Bosmann M, Grailer JJ, Ruemmler R, *et al.*: Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. *FASEB J*. 2013; 27(12): 5010–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  49. Celi A, Pellegrini G, Lorenzet R, *et al.*: P-selectin induces the expression of tissue factor on monocytes. *Proc Natl Acad Sci U S A*. 1994; 91(19): 8767–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  50. Shebuski RJ, Kilgore KS: Role of inflammatory mediators in thrombogenesis. *J Pharmacol Exp Ther*. 2002; 300(3): 729–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
  51. del Conde I, Nabi F, Tonda R, *et al.*: Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. *Arterioscler Thromb Vasc Biol*. 2005; 25(5): 1065–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
  52. Fuchs TA, Bhandari AA, Wagner DD: Histones induce rapid and profound thrombocytopenia in mice. *Blood*. 2011; 118(13): 3708–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  53. Bockmeyer CL, Claus RA, Budde U, *et al.*: Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. *Haematologica*. 2008; 93(1): 137–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
  54. Kremer Hovinga JA, Zeerleder S, Kessler P, *et al.*: ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. *J Thromb Haemost*. 2007; 5(11): 2284–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
  55. Fijnvandraat K, Derks B, Peters M, *et al.*: Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. *Thromb Haemost*. 1995; 73(1): 15–20.
[PubMed Abstract](#)
  56. Amollo CT, Semeraro F, Xu J, *et al.*: Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. *J Thromb Haemost*. 2011; 9(9): 1795–803.
[PubMed Abstract](#) | [Publisher Full Text](#)
  57. Bouwens EA, Stavenuiter F, Mosnier LO: Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. *J Thromb Haemost*. 2013; 11 Suppl 1: 242–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  58. Levi M, van der Poll T: Inflammation and coagulation. *Crit Care Med*. 2010; 38(2 Suppl): S26–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
  59. Massberg S, Grahl L, von Bruehl ML, *et al.*: Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med*. 2010; 16(8): 887–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
  60. Gando S, Levi M, Toh CH: Disseminated intravascular coagulation. *Nat Rev Dis Primers*. 2016; 2: 16037.
[PubMed Abstract](#) | [Publisher Full Text](#)
  61. Wen Z, Liu Y, Li F, *et al.*: Circulating histones exacerbate inflammation in mice with acute liver failure. *J Cell Biochem*. 2013; 114(10): 2384–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
  62. Swystun LL, Mukherjee S, Liaw PC: Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. *J Thromb Haemost*. 2011; 9(11): 2313–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
  63. Kannemeier C, Shibamiya A, Nakazawa F, *et al.*: Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. *Proc Natl Acad Sci U S A*. 2007; 104(15): 6388–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  64. Gando S, Sawamura A, Hayakawa M: Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. *Ann Surg*. 2011; 254(1): 10–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
  65. Hayakawa M: Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype. *J Intensive Care*. 2017; 5: 14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  66. **F** Varjú I, Longstaff C, Szabó L, *et al.*: DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. *Thromb Haemost*. 2015; 113(6): 1289–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  67. **F** Carmona-Rivera C, Zhao W, Yalavarthi S, *et al.*: Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. *Ann Rheum Dis*. 2015; 74(7): 1417–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  68. **F** Gould TJ, Vu TT, Stafford AR, *et al.*: Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. *Arterioscler Thromb Vasc Biol*. 2015; 35(12): 2544–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  69. Levin EG, Marzec U, Anderson J, *et al.*: Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. *J Clin Invest*. 1984; 74(6): 1988–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  70. Hoyer FF, Nickenig G, Werner N: Microparticles—messengers of biological information. *J Cell Mol Med*. 2010; 14(9): 2250–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  71. Deng F, Wang S, Zhang L: Endothelial microparticles act as novel diagnostic and therapeutic biomarkers of circulatory hypoxia-related diseases: a literature review. *J Cell Mol Med*. 2017; 21(9): 1698–710.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
  72. **F** He Z, Si Y, Jiang T, *et al.*: Phosphatidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease. *Thromb Haemost*. 2016; 115(4): 738–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  73. **F** Delabranche X, Stiel L, Severac F, *et al.*: Evidence of Netosis in Septic Shock-Induced Disseminated Intravascular Coagulation. *Shock*. 2017; 47(3): 313–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  74. Gupta AK, Hasler P, Holzgreve W, *et al.*: Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. *Hum Immunol*. 2005; 66(11): 1146–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
  75. Østerud B, Bjørklid E: The tissue factor pathway in disseminated intravascular coagulation. *Semin Thromb Hemost*. 2001; 27(6): 605–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
  76. Shimura M, Wada H, Wakita Y, *et al.*: Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. *Am J Hematol*. 1997; 55(4): 169–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
  77. **F** Stakos DA, Kambas K, Konstantinidis T, *et al.*: Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. *Eur Heart J*. 2015; 36(22): 1405–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
  78. Kambas K, Chrysanthopoulou A, Vassilopoulos D, *et al.*: Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. *Ann Rheum Dis*. 2014; 73(10): 1854–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
  79. **F** Huang YM, Wang H, Wang C, *et al.*: Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. *Arthritis Rheumatol*. 2015; 67(10): 2780–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
  80. Clancy DM, Henry CM, Sullivan GP, *et al.*: Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. *FEBS J*. 2017; 284(11): 1712–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
  81. Hu Z, Murakami T, Tamura H, *et al.*: Neutrophil extracellular traps induce IL-1 β production by macrophages in combination with lipopolysaccharide. *Int J Mol Med*. 2017.
[PubMed Abstract](#) | [Publisher Full Text](#)
  82. Keshari RS, Jyoti A, Kumar S, *et al.*: Neutrophil extracellular traps contain mitochondrial as well as nuclear DNA and exhibit inflammatory potential. *Cytometry A*. 2012; 81(3): 238–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
  83. Keshari RS, Jyoti A, Dubey M, *et al.*: Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. *PLoS One*. 2012; 7(10): e48111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

84. Versteeg HH, Heemskerk JW, Levi M, *et al.*: **New fundamentals in hemostasis.** *Physiol Rev.* 2013; **93**(1): 327–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. **F** Müller F, Mutch NJ, Schenk WA, *et al.*: **Platelet polyphosphates are proinflammatory and procoagulant mediators *in vivo*.** *Cell.* 2009; **139**(6): 1143–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. Abrams ST, Zhang N, Dart C, *et al.*: **Human CRP defends against the toxicity of circulating histones.** *J Immunol.* 2013; **191**(5): 2495–502.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Semeraro F, Ammollo CT, Morrissey JH, *et al.*: **Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4.** *Blood.* 2011; **118**(7): 1952–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Alhamdi Y, Abrams ST, Lane S, *et al.*: **Histone-Associated Thrombocytopenia in Patients Who Are Critically Ill.** *JAMA.* 2016; **315**(8): 817–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Clark SR, Ma AC, Tavener SA, *et al.*: **Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood.** *Nat Med.* 2007; **13**(4): 463–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Carestia A, Kaufman T, Schattner M: **Platelets: New Bricks in the Building of Neutrophil Extracellular Traps.** *Front Immunol.* 2016; **7**: 271.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Esmon CT: **The endothelial cell protein C receptor.** *Thromb Haemost.* 2000; **83**(5): 639–43.
[PubMed Abstract](#)
92. Broze GJ Jr: **Tissue factor pathway inhibitor.** *Thromb Haemost.* 1995; **74**(1): 90–3.
[PubMed Abstract](#)
93. Bombelli T, Mueller M, Haeblerli A: **Anticoagulant properties of the vascular endothelium.** *Thromb Haemost.* 1997; **77**(3): 408–23.
[PubMed Abstract](#)
94. van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, *et al.*: **Studies on the acute release of tissue-type plasminogen activator from human endothelial cells *in vitro* and *in vivo*: evidence for a dynamic storage pool.** *Blood.* 1995; **85**(12): 3510–7.
[PubMed Abstract](#)
95. Suzuki Y, Mogami H, Ihara H, *et al.*: **Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells.** *Blood.* 2009; **113**(2): 470–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Lam FW, Cruz MA, Parikh K, *et al.*: **Histones stimulate von Willebrand factor release *in vitro* and *in vivo*.** *Haematologica.* 2016; **101**(7): e277–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
97. **F** Pieterse E, Rother N, Garsen M, *et al.*: **Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition.** *Arterioscler Thromb Vasc Biol.* 2017; **37**(7): 1371–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
98. Gupta AK, Joshi MB, Philippova M, *et al.*: **Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death.** *FEBS Lett.* 2010; **584**(14): 3193–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Semeraro F, Ammollo CT, Esmon NL, *et al.*: **Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells.** *J Thromb Haemost.* 2014; **12**(10): 1697–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Nesheim ME, Tracy RP, Mann KG: **“Clotspeed,” a mathematical simulation of the functional properties of prothrombinase.** *J Biol Chem.* 1984; **259**(3): 1447–53.
[PubMed Abstract](#)
101. Barranco-Medina S, Pozzi N, Vogt AD, *et al.*: **Histone H4 promotes prothrombin autoactivation.** *J Biol Chem.* 2013; **288**(50): 35749–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. Choi Q, Hong KH, Kim JE, *et al.*: **Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection.** *Ann Lab Med.* 2014; **34**(2): 85–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Asakura H, Ontachi Y, Mizutani T, *et al.*: **Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation.** *Eur J Haematol.* 2001; **67**(3): 170–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. **F** Park HS, Gu J, You HJ, *et al.*: **Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coagulation.** *Thromb Res.* 2016; **138**: 103–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
105. **F** Morrissey JH, Smith SA: **Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.** *J Thromb Haemost.* 2015; **13** Suppl 1: S92–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. Asakura H: **Classifying types of disseminated intravascular coagulation: clinical and animal models.** *J Intensive Care.* 2014; **2**(1): 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Longstaff C, Varjú I, Sótönyi P, *et al.*: **Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones.** *J Biol Chem.* 2013; **288**(10): 6946–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. **F** Allam R, Scherbaum CR, Darisipudi MN, *et al.*: **Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4.** *J Am Soc Nephrol.* 2012; **23**(8): 1375–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
109. Yang R, Zou X, Tenhunen J, *et al.*: **HMGB1 and Extracellular Histones Significantly Contribute to Systemic Inflammation and Multiple Organ Failure in Acute Liver Failure.** *Mediators Inflamm.* 2017; **2017**: 5928078.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. **F** Dieker J, Tel J, Pieterse E, *et al.*: **Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis.** *Arthritis Rheumatol.* 2016; **68**(2): 462–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
111. Gamberucci A, Fulceri R, Marcolongo P, *et al.*: **Histones and basic polypeptides activate Ca²⁺/cation influx in various cell types.** *Biochem J.* 1998; **331**(Pt 2): 623–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. **F** Fattahi F, Grailer JJ, Jajou L, *et al.*: **Organ distribution of histones after intravenous infusion of FITC histones or after sepsis.** *Immunol Res.* 2015; **61**(3): 177–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
113. **F** Kim JE, Lee N, Gu JY, *et al.*: **Circulating levels of DNA-histone complex and dsDNA are independent prognostic factors of disseminated intravascular coagulation.** *Thromb Res.* 2015; **135**(6): 1064–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
114. Walborn A, Patel P, Hoppensteadt D, *et al.*: **Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis Associated Coagulopathy.** *Am Soc Hematology. Blood.* 2016; **128**: 564.
[Reference Source](#)
115. Ekaney ML, Otto GP, Sossof M, *et al.*: **Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation.** *Crit Care.* 2014; **18**(5): 543.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
116. Gao H, Zhang N, Lu F, *et al.*: **Circulating histones for predicting prognosis after cardiac surgery: a prospective study.** *Interact Cardiovasc Thorac Surg.* 2016; **23**(5): 681–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. **F** Stiel L, Delabranche X, Galois AC, *et al.*: **Neutrophil Fluorescence: A New Indicator of Cell Activation During Septic Shock-Induced Disseminated Intravascular Coagulation.** *Crit Care Med.* 2016; **44**(11): e1132–e1136.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
118. Wildhagen KC, García de Frutos P, Reutelingsperger CP, *et al.*: **Nonanticoagulant heparin prevents histone-mediated cytotoxicity *in vitro* and improves survival in sepsis.** *Blood.* 2014; **123**(7): 1098–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. **F** Savchenko AS, Borisoff JI, Martinod K, *et al.*: **VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.** *Blood.* 2014; **123**(1): 141–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Julie Helms

Strasbourg University Hospital, Strasbourg, France

Competing Interests: No competing interests were disclosed.

2. Craig N Jenne

Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Canada

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research